Chitosan Nanovaccines as Efficient Carrier Adjuvant System for IL-12 with Enhanced Protection Against HBV

PURPOSE: Alum adjuvant in HBV prophylactic vaccines is poor in inducing cellular immunity with the inhibition of IL-12 secretion, and approximately 5–10% of immunised individuals fail to clear HBV upon infection. IL-12 plasmids (pIL-12) as adjuvants enhance significant humoral and cellular immune re...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Huajun, Wang, Haigang, Hu, Yifei, Xu, Dongqing, Yin, Chunlai, Han, Qiuju, Zhang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312321/
https://www.ncbi.nlm.nih.gov/pubmed/34321879
http://dx.doi.org/10.2147/IJN.S317113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8312321/
https://www.ncbi.nlm.nih.gov/pubmed/34321879
http://dx.doi.org/10.2147/IJN.S317113

Ejemplares similares